Skip to content
Search

Latest Stories

Bolton locum pharmacist receives three-month suspension for workplace sexual misconduct

The Fitness-to-Practise Committee of the General Pharmaceutical Council has issued a three-month suspension to Mohammed Roohul Haque (Reg No: 2226084), a locum pharmacist, due to incidents of workplace sexual misconduct.

According to the determination document issued by the regulatory body, Haque undertook the position of a locum pharmacist at Hollowood Chemists on July 12. It was during this period that he encountered the dispenser (referred to as the "complainant"), a 40-year-old co-worker at the pharmacy, for the first instance. Following this initial meeting, he proceeded to engage in making explicit sexual comments.


During the lunch break of the pharmacy's second dispenser, Haque asked the dispenser, who had lodged the complaint, to review photographs displayed on his mobile phone, depicting renovations being carried out at his residence. The initial images focused on the ongoing renovation activities. However, he later switched to displaying a full-screen photograph of his erect penis, the document said.

Despite the fact that the dispenser promptly distanced herself, Haque persisted in discussing the photograph with her. He went so far as to apologise, and even asked if she had managed to closely observe the picture.

On the following day, July 13, 2021, the dispenser filed a formal complaint regarding Haque's misconduct with Hollowood's superintendent pharmacist. She also indicated her intention to report the incident to the General Pharmaceutical Council (GPhC), as mentioned in the document.

The case hearing took place from July 24 to 26.

Haque conceded to displaying a photograph of his erect penis to the dispenser, along with making remarks concerning her physical appearance. He acknowledged that his actions were inappropriate. However, he labelled the comments as banter and contended that he had unintentionally accessed the explicit picture, as detailed in the document.

The Committee, however, found Haque's explanation less convincing given the case's facts. He stated his comments were aimed at establishing a positive working relationship, but this contradicted evidence that he spent most of the morning on his mobile phone rather than assisting in the dispensary, as noted by the Committee.

It also took into consideration the Council's publication "Good decision-making" (revised March 2017) to understand the concept of 'fitness to practise’. Paragraph 2.11 reads: “A pharmacy professional is ‘fit to practise’ when they have the skills, knowledge, character, behaviour and health needed to work as a pharmacist…safely and effectively. In practical terms, this means maintaining appropriate standards of competence, demonstrating good character, and also adhering to the principles of good practice set out in your various standards, guidance and advice.”

The Committee reached the conclusion that Haque had intentionally displayed the image with the aim of seeking sexual satisfaction or pursuing a sexual connection. It further stated that he had misused his professional status, given that the individual impacted by his misconduct was a subordinate.

It further noted that Haque's misconduct was tempered by the fact that it occurred on a single day and did not involve any physical contact. As outlined in its decision, this placed the sexual misconduct at the less severe end of the spectrum.

The Committee found the allegations amounted to misconduct and chose to suspend Haque from the registry for three months, as detailed in the document. It also noted that a brief suspension period sufficed to signify the gravity of the registrant's inappropriate sexual behaviour, given his authentic understanding, remorse, and meaningful actions taken to address the matter.

Meanwhile, a noticeable shift in community pharmacy work patterns is occurring, with a greater reliance on locum pharmacists in the staffing model, according to 2022 Community Pharmacy Workforce Survey by NHS England. While employed pharmacists decreased by 16 per cent from 12,774 in 2021 to 10,943 in 2022, locum pharmacists increased by 26 per cent from 4,297 in 2021 to 5,477 in 2022. This trend persists even though locum pharmacists, on average, work fewer hours.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less